CHEMFAB CHEMFAB NSE
Company Profile ↓Company Overview
CHEMFAB (CHEMFAB) is a publicly traded company listed on NSE with a market capitalization of ₹539.01 Cr. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.34.
Recent Developments
- Mar 2026 Revenue of ₹311.02 Cr (-7.0% YoY); net profit ₹-3.43 Cr.
- Trailing 12 Months Year-on-year growth — revenue -7.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.69% |
| 1 Year: | -6.98% |
Stock Price Performance
| 1 Year: | -51.35% |
| 6 Months: | -14.88% |
| 3 Months: | -4.29% |
| 1 Month: | -2.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.54 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 52.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 73.30 Cr | 79.08 Cr | 79.58 Cr | 86.33 Cr | 82.31 Cr | 76.53 Cr | 81.90 Cr | - | 92.32 Cr | 91.54 Cr | 76.56 Cr | 68.14 Cr | 74.78 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 60.20 Cr | 60.23 Cr | 53.28 Cr | 49.86 Cr | 51.91 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 32.12 Cr | 31.31 Cr | 23.28 Cr | 18.29 Cr | 22.87 Cr |
| Operating Expenses | 48.77 Cr | 63.59 Cr | 68.70 Cr | 71.13 Cr | 69.98 Cr | 68.20 Cr | 71.75 Cr | - | 29.39 Cr | 26.41 Cr | 24.43 Cr | 23.81 Cr | 22.30 Cr |
| Operating Income | 19.07 Cr | 10.07 Cr | 5.26 Cr | 9.75 Cr | 6.47 Cr | 1.02 Cr | 1.35 Cr | - | 2.73 Cr | 4.91 Cr | -1.15 Cr | -5.53 Cr | 56.66 L |
| EBITDA | 24.53 Cr | 15.49 Cr | 10.88 Cr | 15.20 Cr | 12.33 Cr | 8.33 Cr | 10.15 Cr | - | 4.82 Cr | 12.66 Cr | 7.22 Cr | 4.71 Cr | 11.32 Cr |
| Interest Expense | 4.00 L | 5.00 L | 6.00 L | 43.00 L | 41.00 L | 94.00 L | 1.22 Cr | - | 1.57 Cr | 1.57 Cr | 1.94 Cr | 2.03 Cr | 2.14 Cr |
| Pretax Income | 20.53 Cr | 13.70 Cr | 6.66 Cr | 10.83 Cr | 7.96 Cr | 2.67 Cr | 73.00 L | - | -7.35 Cr | 4.70 Cr | -1.33 Cr | -4.79 Cr | 1.23 Cr |
| Tax Provision | 5.26 Cr | 4.19 Cr | 2.36 Cr | 3.72 Cr | 2.55 Cr | 1.78 Cr | 1.26 Cr | - | 1.84 Cr | 2.15 Cr | 67.92 L | -34.54 L | 74.04 L |
| Net Income | 15.26 Cr | 9.51 Cr | 4.30 Cr | 7.10 Cr | 5.41 Cr | 90.00 L | -53.00 L | - | -9.19 Cr | 2.55 Cr | -2.01 Cr | -4.45 Cr | 48.46 L |
| Diluted EPS | 10.76 | 6.70 | 3.03 | 4.99 | 3.80 | 0.63 | -0.37 | - | -6.41 | 1.77 | -1.40 | -3.09 | 0.34 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 205.00 Cr | 181.00 Cr | - | 331.12 Cr | 327.30 Cr | 334.37 Cr | 311.02 Cr |
| Cost of Revenue | - | - | - | 174.41 Cr | 210.33 Cr | 218.45 Cr | 215.28 Cr |
| Gross Profit | - | - | - | 156.71 Cr | 116.96 Cr | 115.92 Cr | 95.75 Cr |
| Operating Expenses | 149.00 Cr | 157.00 Cr | - | 68.72 Cr | 85.42 Cr | 108.53 Cr | 96.95 Cr |
| Operating Income | 30.00 Cr | 4.00 Cr | - | 87.99 Cr | 32.25 Cr | 7.39 Cr | -1.20 Cr |
| EBITDA | 55.00 Cr | 24.00 Cr | - | 112.61 Cr | 62.44 Cr | 40.95 Cr | 35.91 Cr |
| Interest Expense | 4.00 Cr | 3.00 Cr | - | 24.48 L | 94.22 L | 4.92 Cr | 7.69 Cr |
| Pretax Income | 27.00 Cr | 2.00 Cr | - | 89.44 Cr | 39.15 Cr | -30.54 L | -20.00 L |
| Tax Provision | 1.35 Cr | 10.00 Cr | - | 24.86 Cr | 12.82 Cr | 6.63 Cr | 3.23 Cr |
| Net Income | 25.00 Cr | -8.00 Cr | - | 64.58 Cr | 26.32 Cr | -6.94 Cr | -3.43 Cr |
| Diluted EPS | 18.26 | -5.78 | 20.20 | 45.14 | 18.34 | -4.86 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | 348.00 Cr | 335.00 Cr | - | 412.10 Cr | 500.32 Cr | 521.82 Cr | 576.73 Cr |
| Current Assets | - | - | - | 124.43 Cr | 100.58 Cr | 119.37 Cr | 127.19 Cr |
| Cash & Equivalents | - | - | - | 98.39 L | 2.34 Cr | 4.70 Cr | 8.46 L |
| Inventory | - | - | - | 16.94 Cr | 16.01 Cr | 27.18 Cr | 25.90 Cr |
| Receivables | - | - | - | 21.73 Cr | 21.22 Cr | 20.77 Cr | 24.08 Cr |
| Total Liabilities | - | - | - | 50.74 Cr | 113.06 Cr | 141.83 Cr | 201.33 Cr |
| Current Liabilities | - | - | - | 45.90 Cr | 91.86 Cr | 72.20 Cr | 113.34 Cr |
| Long Term Debt | - | - | - | 0 | 16.39 Cr | 63.80 Cr | 81.43 Cr |
| Total Debt | 43.00 Cr | 32.00 Cr | - | 2.36 Cr | 20.11 Cr | 84.34 Cr | 125.76 Cr |
| Total Equity | 276.00 Cr | 267.00 Cr | - | 361.35 Cr | 387.26 Cr | 379.99 Cr | 375.41 Cr |
| Shares Outstanding | - | - | - | 1.42 Cr | 1.42 Cr | 1.44 Cr | 1.44 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 54.00 Cr | 45.00 Cr | - | 92.59 Cr | 31.35 Cr | 39.91 Cr | 38.09 Cr |
| Investing Cash Flow | -58.00 Cr | -6.00 Cr | - | -47.51 Cr | -109.53 Cr | -85.99 Cr | -80.60 Cr |
| Financing Cash Flow | 3.00 Cr | -16.00 Cr | - | -8.89 Cr | 16.06 Cr | 58.72 Cr | 30.57 Cr |
| Capital Expenditure | -58.00 Cr | -7.00 Cr | -20.20 Cr | -57.61 Cr | -91.92 Cr | - | -91.22 Cr |
| Free Cash Flow | -4.00 Cr | 38.00 Cr | - | 34.98 Cr | -60.57 Cr | -73.48 Cr | -53.13 Cr |
| Net Change in Cash | -1.00 Cr | 23.00 Cr | - | 36.19 Cr | -62.11 Cr | 12.65 Cr | -11.94 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 47.3% | 35.7% | 34.7% | 30.8% |
| Operating Margin % | 14.6% | 2.2% | - | 26.6% | 9.9% | 2.2% | -0.4% |
| Net Margin % | 12.2% | -4.4% | - | 19.5% | 8.0% | -2.1% | -1.1% |
| ROE % | 9.1% | -3.0% | - | 17.9% | 6.8% | -1.8% | -0.9% |
| ROCE % | - | - | - | 24.0% | 7.9% | 1.6% | -0.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CHEMFAB
Chemfab Alkalis Posts ₹5M Q4 Profit Swinging from ₹92M Loss as Revenue Dips 19% - Sahi
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOR1I3bjA0d1VUam5iVFRWQWkxdmdHYUtWVW1kaFFlOHBwaVFsdTVRMU4zckFjX3plVi1ScURlaVZyS01lSFlSUV9YbjVGT3Uxc29BZktVYjR5UjNIOHVOa3dxZEdERWNQNTFvdFRoOVU5aWdySFdTaDRLSkQydHNOcTBMeVQtcHpjb3hCN2…
Chemfab invests ₹14.9 crore in Zenataris Renewable - scanx.trade
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQVkFhMnJTZEhMRUVYQjRmVWhPZG44clQ1NUhKdjZfRDhXajJnLVAxQ2Ywc3c0djFtVXQzNnVGcW1oMVJTbzNZVEphYlhJeldvNjZKUVJSMkhhcHNrTkNSSjZ4dElHM0pqSkNCaDc5ZUtCVWQ3cFNEWVZveWJxS0REUW9fTkVKdjI3TEpVc1…
TRANSPEK Stock Price and Chart — NSE:TRANSPEK - TradingView
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE5laVBtWjV4RWxJajBSdE1tRTRLWDRGWThMT2QwNzdvbEdlVFFMMmxldVpGajVUREpuaVlhUVpXN1o1aEdoYkl1NTVLZTlMN09McmdVVDhOWnlWUlNWTVE?oc=5" target="_blank">TRANSPEK Stock Price and Chart — NSE:TRA…
Evaluating Carbon Stock and Biodiversity Dynamics in Chemfab Alkalis Limited’s Plantations: A Comparative Study Across 2014, 2020 and 2025 - TERI
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOMHFXLUJ0dElvZXZYZlZmZWVXTUJYT2hUT2t3ZU96S2NUMU1mOFhFWk1felZIUmR3V1V5Z0RCWEQ4WFBBQnlvR0JmX0dpU3RZdmpJd04zSDRrMFhqTnBhcGlocktRV1JpbWlNSUR1b0ZsWTV3eldvMGpIYlhjOEpQX1RVZzhwaHRVano4YT…
Chemfab Alkalis FY26 Net Profit Rs 750.59 Lakh; Dividend Rs 1.25 Per Share - scanx.trade
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOTjRfUHdhSlAycGUxYURDVnNSQjJzTGc2OExPcXZCU3JVODJtVDV4YlA3Wng4em42ZzBfczJxb1JOTHMweGwzUWxsUGVteFA0OHBud2RhNno1V0JnRFdOWWNxVDcyWFQzcHdqRGNRbEhodU9RRG1mTHZJQk9aVWh3SmdpcEgxTjgxaUw4aU…
FIIs turn bullish: Raise stakes in these 9 smallcap stocks after two quarters of trimming - The Economic Times
<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxPSHQ1OEwtTUtEeUVTOW42U09rV1dfZ3RVUW5BeF9TZGRfUGRRTFhnck54VTlJUWM4MkZBeDlwLVd4T0JoLWJhQTZMdkt6SnpVZkI5N3RreE1ZTWdaREVjdWRJaHdoTlBQQUJCazRaRlptc2JNTHh1SFZOcnZLLTQtMXZ2THc0Z2xJV3pwbX…
CHEMFAB — Frequently Asked Questions
What is the current share price of CHEMFAB?
As of 2026-07-15 09:52 IST, CHEMFAB trades at ₹375.00 on NSE. Its 52-week range is ₹292.90 to ₹788.90.
What is the market capitalisation of CHEMFAB?
CHEMFAB has a market capitalisation of ₹539.01 Cr on NSE.
What is the P/E ratio of CHEMFAB?
CHEMFAB trades at a trailing price-to-earnings (P/E) ratio of -77.16. Its price-to-book (P/B) ratio is 1.42.
What is the return on equity (ROE) of CHEMFAB?
CHEMFAB has a return on equity (ROE) of -0.91%. Its return on capital employed (ROCE) is -0.26%.
Is CHEMFAB a good stock to buy?
This page provides a data-driven analysis of CHEMFAB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.